GENEVA and CAMBRIDGE, Mass., Oct. 24, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical studies of IPI-926, Infinity's oral Hedgehog pathway inhibitor currently in Phase 1 clinical development, demonstrate that the compound significantly down-regulates Hedgehog signaling in tumor stroma, thereby disrupting the communication process between tumor and stroma, ultimately leading to tumor growth inhibition. Data reported today also show that in a preclinical model of human pancreatic cancer, daily administration of IPI-926 results in significant tumor growth inhibition when compared to vehicle controls. These data were presented at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland.
